Gilead Sciences, Inc.

GILD

US3755581036

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
65.42 ^USD	+0.23%		-2.01%	-19.24%

Apr. 26	TD Cowen Adjusts Price Target on Gilead Sciences to $85 From $90	MT
Apr. 26	Jefferies Adjusts Gilead Sciences' Price Target to $80 From $95	MT

Gilead Sciences, Inc. announced that it has received $210 million in funding from Abingworth LLP

March 03, 2024

Gilead Sciences, Inc. announced a private placement that it has received $210,000,000 in funding on March 4, 2024. The transaction will include participation from returning investor, Abingworth LLP.

Latest news about Gilead Sciences, Inc.

TD Cowen Adjusts Price Target on Gilead Sciences to $85 From $90	Apr. 26	MT
Jefferies Adjusts Gilead Sciences' Price Target to $80 From $95	Apr. 26	MT
RBC Capital Adjusts Gilead Sciences' Price Target to $74 From $76	Apr. 26	MT
Morgan Stanley Adjusts Price Target on Gilead Sciences to $78 From $80	Apr. 26	MT
Gilead Sciences Receives FDA Approval for Updated Label of Biktarvy	Apr. 26	MT
Well, it isn't as bad as feared...	Apr. 26
Gilead Sciences, Inc. Announces U.S. Food and Drug Administration Approve Biktarvy® Label Update With Data for Pregnant Adults With HIV	Apr. 26	CI
News Highlights : Top Company News of the Day - Friday at 1 AM ET	Apr. 26	DJ
News Highlights : Top Company News of the Day - Thursday at 11 PM ET	Apr. 25	DJ
News Highlights : Top Company News of the Day - Thursday at 9 PM ET	Apr. 25	DJ
News Highlights : Top Company News of the Day - Thursday at 5 PM ET	Apr. 25	DJ
News Highlights : Top Company News of the Day - Thursday at 7 PM ET	Apr. 25	DJ
Gilead Sciences Q1 Tops Estimates, Updates Outlook	Apr. 25	MT
Gilead Sciences Posts Higher 1Q Sales, Swings to Loss on Charges	Apr. 25	DJ
Transcript : Gilead Sciences, Inc., Q1 2024 Earnings Call, Apr 25, 2024	Apr. 25
(GILD) GILEAD SCIENCES Forecasts Fiscal Year 2024 EPS Range $3.45 - $3.85	Apr. 25	MT
Earnings Flash (GILD) GILEAD SCIENCES Reports Q1 Revenue $6.69B, vs. Street Est of $6.348B	Apr. 25	MT
Gilead Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 25	CI
Gilead posts quarterly loss, revenue rises 5%	Apr. 25	RE
Gilead Sciences, Inc. Revises Earnings Guidance for the Full Year 2024	Apr. 25	CI
Gilead Sciences, Inc. Declares a Dividend for the Second Quarter of 2024, Payable on June 27, 2024	Apr. 25	CI
North American Morning Briefing : More Tech -2-	Apr. 25	DJ
HSBC Upgrades Gilead Sciences to Hold From Reduce, Price Target is $69	Apr. 24	MT
Argus Cuts Price Target on Gilead Sciences to $75 From $85	Apr. 23	MT
Cantor Fitzgerald Adjusts Gilead Sciences' Price Target to $75 From $78, Maintains Neutral Rating	Apr. 22	MT

Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).

Sector

Pharmaceuticals

Calendar

2024-05-08 - Annual General Meeting

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for Gilead Sciences, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

65.42 USD

Average target price

84.25 USD

Spread / Average Target

+28.78%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
GILEAD SCIENCES, INC.	-19.24%	81.58B
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals